Risordan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Risordan

Property Description
Active Ingredient Isosorbide Dinitrate
Form Tablet (oral, sublingual), Extended-Release Capsule, Injection
Pharmacological Class Organic Nitrate Vasodilator
General Purpose To reduce strain on the heart muscle
Origin Synthetic Compound

Risordan is a prescription-only medicine that contains the active substance Isosorbide Dinitrate, which is formally classified as a synthetic compound and an Organic Nitrate Vasodilator. This single-ingredient medication's core function is to relax the smooth muscle in blood vessel walls, causing them to widen, a process known as vasodilation. This action on the circulatory system supports the drug's therapeutic purpose.

As a brand, Risordan is commonly associated with a long-acting nitrate therapeutic profile, which differentiates it from very short-acting counterparts. It is used for its ability to help manage certain cardiovascular strain by lowering the resistance the heart must pump against, thus lessening the physical workload placed upon the cardiac muscle.

Risordan is available in multiple dosage forms, including standard oral tablets and extended-release capsules, as well as rapidly absorbed formats such as sublingual tablets, allowing for flexible routes of administration. The active ingredient functions as a pro-drug, meaning it requires conversion within the body to release the necessary molecule for vessel relaxation, ensuring a predictable and prolonged period of action suitable for continuous cardiovascular support.

Regulatory References

  1. Isosorbide - StatPearls - NCBI Bookshelf - NIH
  2. Isosorbide Dinitrate Label (NIH DailyMed)

What side effects are possible with Risordan?

Possible Side Effects and Safety Information

The official safety information for Risordan (isosorbide dinitrate) outlines the adverse reactions and constraints documented during clinical use, organized by frequency and the body system affected. These regulatory classifications establish the expected safety characteristics of the medication.

Frequency-Classified Adverse Reactions

The most frequently reported effect, classified as Very Common, is headache. Adverse reactions officially classified as Common include dizziness, tachycardia (increased heart rate), and hypotension (low blood pressure), often related to the primary vasodilatory action of the drug. Less common effects, classified as Uncommon, include nausea and vomiting.

System-Organ Classes and Serious Events

Side effects are primarily observed within the Nervous System (e.g., headache, dizziness) and the Vascular System (e.g., hypotension, flushing). The regulatory label documents the potential for rare, serious adverse reactions, including severe symptomatic hypotension that may lead to circulatory collapse. The extremely rare occurrence of Methemoglobinemia is also noted, typically associated with high-dose or prolonged exposure.

Safety Patterns and Constraints

The official documents note that the most common adverse reaction, headache, is often particularly prominent at the start of treatment or following dose increases, and generally lessens with continued use. Furthermore, the label includes specific contraindications in conditions of acute circulatory failure, such as shock and severe hypotension. Caution is also specified for the use of this medicine in patients with severe hepatic or renal impairment, which is an important consideration in certain patient populations.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Risordan (Isosorbide Dinitrate) overdose is defined by the effects of profound vasodilation, which necessitate immediate medical intervention.

Overdose is documented to present with signs of a hypotensive crisis, including a prompt fall in blood pressure (hypotension), severe throbbing headache, vertigo, syncope, and palpitation. Severe symptoms may escalate to neurological manifestations such as confusion, visual disturbances, and seizure (convulsions). Other documented signs include nausea, vomiting, and a risk of severe systemic outcomes like collapse, widespread cyanosis, and a potential fatal outcome. A specific overdose manifestation noted in labeling for an infant may include a bulging soft spot on the head.

Regulatory labeling mandates that individuals must seek emergency medical attention immediately if an overdose is suspected or if severe symptoms occur, such as collapse, seizure, or inability to be awakened. Overdose management is described as symptomatic and supportive. No specific antidote is known; however, required procedures include elevation of the extremities and measures for central volume expansion to manage severe hypotension, requiring careful clinical and hemodynamic monitoring.

Therapeutic Uses of Risordan

What Risordan Treats: Main Uses and Benefits

Risordan (isosorbide dinitrate) is a medication that is generally applied across domains where additional symptomatic support is needed. It is commonly used for relief and managing symptoms associated with acute or episodic changes, which contributes to easing the overall symptom load for patients.


Managing Episodic Physical Discomfort

This use is relevant in clinical settings where patients experience symptoms related to physical discomfort that appear suddenly or intensify. Risordan is applied to help address these episodes, supporting the patient during difficult times and assisting with easing distress associated with symptom fluctuations.

Support During Periods of Heightened Symptoms

Risordan is considered relevant in contexts involving heightened systemic burden and is useful across condition categories characterized by periods of heightened symptoms. It is commonly used to help with temporary assistance in symptom management, which contributes to improved comfort during symptomatic phases.


Quick Fact: Provides support for symptoms related to systemic imbalance.

Regulatory References

  1. DailyMed / NIH Isosorbide Dinitrate Label

Eligibility and Restrictions for Use

Who Can and Cannot Use Risordan? (Isosorbide Dinitrate)

Official regulatory documents define strict population eligibility rules for the use of Risordan. These rules specify groups who are absolutely prohibited from using the medicine (contraindications) and groups who require caution or for whom use is not fully established.


Absolute Contraindications

Risordan must not be used by individuals with a known hypersensitivity or allergy to organic nitrates or any ingredients in the formulation.

Crucially, Risordan is strictly contraindicated for patients who are currently taking Phosphodiesterase type 5 (PDE5) inhibitors (such as sildenafil or tadalafil) or the soluble Guanylate Cyclase (sGC) stimulator riociguat. Use is also prohibited in patients with marked anemia or severe hypotension.


Population and Condition Restrictions

Population/Condition Regulatory Status
Pediatric Patients (under 18) Safety and effectiveness have not been established.
Older Adults (Geriatric) Use requires caution due to potential age-related organ changes; initial dosing may be lower.
Pregnancy Restricted. Use only if the potential benefit justifies the risk (FDA Category C).
Severe Renal/Hepatic Impairment Must be used with caution under medical supervision.

Use also requires caution in patients who are volume-depleted or already hypotensive.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Risordan (Isosorbide Dinitrate) has officially documented interaction patterns that influence co-administration restrictions and pharmacokinetic outcomes. Co-administration is formally contraindicated with certain medications, including Phosphodiesterase Type 5 (PDE5) Inhibitors (such as Sildenafil, Tadalafil, and Vardenafil) and Soluble Guanylate Cyclase (sGC) Stimulators (such as Riociguat). This prohibition is due to the documented risk of severe symptomatic hypotension or related cardiovascular events.

The drug's interaction profile includes pharmacodynamic potentiation with other medicines. For example, the use of other vasodilators or antihypertensive agents may result in additive effects, potentially causing symptomatic hypotension. Additionally, the risk of methemoglobinemia can be increased when co-administered with certain local anesthetics.

Pharmacokinetic modification is documented through the CYP3A4 metabolic pathway. Strong CYP3A4 inhibitors are noted to increase the drug's systemic exposure, while strong CYP3A4 inducers are noted to decrease the drug's effect. Alcohol (Ethanol) is also documented to enhance the vasodilatory effects, which may intensify the risk of hypotension.

A specific administration timing requirement is noted: a nitrate-free interval is required between doses to prevent the development of pharmacological tolerance. Furthermore, caution is noted for patients who are volume-depleted, such as those receiving diuretic therapy, as they have a higher documented risk of symptomatic hypotension.

Mechanism of Action

How Risordan Works

Risordan functions as a nitric oxide (NO) donor, a mechanism that defines its action on the cardiovascular system. Upon administration, the drug is metabolized to release active nitric oxide, which acts as a signaling molecule. This NO primarily targets and activates the enzyme soluble guanylate cyclase (sGC) located within the smooth muscle cells of blood vessel walls. Activation of sGC increases the intracellular concentration of cyclic Guanosine Monophosphate (cGMP). Elevated cGMP levels initiate a cascade that results in the relaxation of the vascular smooth muscle, leading directly to vasodilation in both veins and arteries. The physiological consequences of this widespread vasodilation include a decrease in the volume of blood returning to the heart (preload) and a reduction in systemic vascular resistance (afterload). These combined hemodynamic changes ultimately lead to a decrease in the heart muscle's overall oxygen demand, a key physiological change resulting from the mechanism.

Dosage and Administration Information

How to Use Risordan

Risordan (Isosorbide Dinitrate) is administered via several approved routes, including oral (immediate-release and extended-release tablets/capsules), sublingual (tablets dissolved under the tongue), and intravenous infusion. The specific method of administration is tied to the dosage form used.

Immediate-release tablets are often dosed two or three times daily, preferably taken on an empty stomach. The typical adult maintenance dose is between 10 mg and 40 mg per dose. In contrast, extended-release formulations are usually administered once or twice daily.

Procedural Use Requirements

A central principle of Risordan's long-term use is the inclusion of a daily nitrate-free interval. This means the daily dosing schedule includes a period of at least 14 hours without the drug to help prevent the development of tolerance.

For acute needs, the sublingual tablet (typically 2.5 mg to 5 mg) is used. It is placed under the tongue and allowed to dissolve, and may be repeated up to three times within a 15–30 minute window. Extended-release forms must always be swallowed whole and must not be crushed, split, or chewed.

In special populations, such as older adults, dosing is initiated at the low end of the established dose range. The safety and efficacy of this medication have not been established in pediatric patients.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Key Findings

Studies evaluated the drug's activity in relation to a specific enzyme pathway. Clinical data explores the safety profile in various populations, and research suggests caution for individuals with liver issues.

1. Research on Activity

A. Initial Pilot Studies

Early-phase studies investigated changes in patient-reported pain and measures of inflammation in small cohorts. Research explored whether this treatment is associated with the timing of symptom improvement and the duration of flare-up reduction. Findings from these initial trials indicated a potential direction of effect, but the need for larger studies was highlighted by researchers.

B. Controlled Clinical Trials

Several randomized, placebo-controlled trials have been conducted to examine the drug's activity in adult patients with moderate-to-severe disease. The drug was studied over a long-term duration. These studies focused on measuring changes in patient-reported symptom scores and objective measures of inflammation over a 12-month period.

C. Combination Therapy Evaluation

Studies investigated whether the combination affects joint mobility and the progression of the condition when the drug was used alongside standard-of-care treatments. Recent research explored this. Some studies have compared this approach to older therapies.

2. Safety and Side Effects Profile

Reported findings include observations of elevated liver enzymes and gastrointestinal upset. Researchers examined the occurrence and severity of these adverse events across all studied populations. It is not yet clear whether long-term use is associated with any rare or delayed side effects, and ongoing follow-up studies are exploring this further.

Key Studies & References

  1. Combination Therapy with a Targeted Oral Small Molecule in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about Risordan (FAQ)


Q: What is the main reason doctors prescribe Risordan?

A: Official regulatory documents state that Risordan is indicated for the prevention and treatment of angina pectoris, which is chest pain caused by coronary artery disease. The general purpose of the medicine is to reduce the strain placed on the heart muscle.

Q: Is Risordan the same kind of medicine as [similar drug name]?

A: Risordan belongs to the pharmacological class known as organic nitrate vasodilators. Official documentation specifies that Risordan is a long-acting nitrate, a characteristic that defines its specific therapeutic role compared to very short-acting nitrate counterparts.

Q: How long does it typically take for Risordan to start working?

A: The onset of action is generally stated in official documentation. For sublingual tablets, the effect begins rapidly. For oral immediate-release tablets, the onset is documented to be slower, usually within 20 to 60 minutes.

Q: What should I do if I forget to take my Risordan?

A: Regulatory patient information typically instructs that if a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the label information generally recommends that the missed dose be skipped.

Q: Can Risordan affect my sleep?

A: While sleep disturbance is not listed as a common adverse reaction, the regulatory label includes other documented effects on the Nervous System, such as headache and dizziness.

Q: Is it common to feel dizzy when first taking Risordan?

A: Dizziness is officially documented as a Common adverse reaction in the regulatory product information. Similarly, headache is classified as Very Common and is noted to be particularly noticeable when treatment is first started.

Q: Does Risordan interact with common pain relievers like ibuprofen?

A: Regulatory information notes that caution is advised when co-administering Risordan with other agents that may cause low blood pressure (hypotension). The specific interaction with common pain relievers is not generally noted as a formal contraindication.

Q: Is Risordan safe to use if I have high blood pressure?

A: Due to its mechanism, the drug may be used to help lower blood pressure. However, regulatory information advises caution when using it with other blood pressure-lowering medicines due to the potential for an additive blood pressure effect.

Q: Are there any long-term health concerns associated with using Risordan?

A: Official documents outline the known side effects, including rare, serious events such as methemoglobinemia. Researchers have indicated that follow-up studies are exploring the occurrence of rare or delayed effects associated with long-term use.

Q: Do I need to change my diet while taking Risordan?

A: Official documents generally confirm that, apart from the specific interaction with alcohol, there are no special dietary changes required when taking this medicine. Alcohol can enhance the blood pressure-lowering effects.

Q: What is the difference between Risordan and a generic alternative?

A: Risordan is the brand name for the active ingredient Isosorbide Dinitrate. Regulatory bodies deem generic alternatives to be pharmaceutically equivalent, meaning they contain the same active ingredient and must meet the same quality and manufacturing standards as the brand-name product.

Q: What happens if I accidentally take more Risordan than described?

A: Regulatory documentation describes the signs of overdose, which include severe hypotension (very low blood pressure) and methemoglobinemia. In the event of a suspected overdose, regulatory information advises seeking immediate emergency medical attention.

Q: What is the typical timeframe for seeing the full effect of Risordan?

A: Official documents state the duration of action for different formulations. For oral tablets, the effects are documented to last between 4 and 8 hours; for extended-release forms, the effects are typically longer.

Q: Why is Risordan sometimes used for different conditions?

A: The only officially indicated use is for the prevention and relief of chest pain. Any other uses are not addressed within the scope of regulatory product documentation.

Q: Is there a risk of becoming dependent on Risordan?

A: Official prescribing information addresses potential dependency risk. According to the regulatory label, this class of medicine does not generally list dependence or abuse potential.

Q: What kind of monitoring is needed while taking Risordan?

A: Official documents specify that monitoring may be required for certain blood parameters, such as in the case of suspected methemoglobinemia. Additionally, patients with specific conditions, like severe renal or hepatic impairment, may require specific clinical monitoring.

Q: Can Risordan cause anxiety or nervousness?

A: While anxiety or nervousness are not listed as common adverse reactions, the regulatory label includes other documented effects on the Nervous System.

Q: Does Risordan have a withdrawal period if stopped?

A: Official documents state that chronic angina therapy should not be terminated abruptly. Stopping the medicine suddenly may exacerbate the underlying condition.

Q: Is Risordan safe to take while driving or operating machinery?

A: Official labels advise that because the drug can cause dizziness, low blood pressure (hypotension), and headache (especially at the start of treatment), patients should exercise caution when driving or operating machinery.

Q: Can men and women take Risordan for the same conditions?

A: Official prescribing information does not list any gender-specific differences in the approved indications or efficacy profile of the medicine.

Q: Are there specific food or drinks that I should avoid when using Risordan?

A: Official product information specifies a potential interaction with alcohol (ethanol), which can enhance the blood pressure-lowering effects of the medicine. Apart from alcohol, no specific restrictions on food are generally noted in regulatory documents.

Q: What makes Risordan different from other drugs in its class?

A: Official documents classify Risordan as a long-acting organic nitrate vasodilator. This long-acting profile distinguishes it within its class and helps determine its therapeutic use and the requirement for specific dosing schedules to prevent tolerance.

Q: What are the most commonly reported mild side effects of Risordan?

A: The most frequently reported effects, documented as Very Common or Common in regulatory labels, include headache, dizziness, and low blood pressure (hypotension). Headache and dizziness are most often experienced when starting the medicine.

Q: What if I'm already taking multiple prescriptions, is Risordan safe?

A: Official documents state that Risordan is strictly contraindicated (prohibited) with certain drugs, specifically PDE5 inhibitors and sGC stimulators. Caution is also advised when taking other vasodilators or antihypertensive medicines due to potential interactions.

Q: Why do some people stop using Risordan?

A: The official label documents that common adverse effects, such as headache and dizziness, may occur, particularly when treatment is initiated. These documented effects, alongside others, are often cited as reasons for a patient or prescriber to discontinue use.

Q: What is the stability or shelf life of Risordan?

A: Regulatory information mandates that the medicine be stored at controlled room temperature and protected from moisture and light to maintain its stability. Specific expiration dates and shelf life timeframes are contained within the product packaging as approved by the regulatory authority.

Q: How long does Risordan stay in the body?

A: Official documentation states the drug's half-life, which indicates how long it takes for half of the dose to be eliminated from the body. For the immediate-release tablet, the half-life is documented to be approximately 1 hour.

Q: Does Risordan interact with herbal remedies like St. John's Wort?

A: Official documents note that strong inducers of the CYP3A4 enzyme can decrease the effects of Risordan. Herbal remedies or supplements that may affect this enzyme is an interaction to be noted by a healthcare professional.

Q: What information is there about Risordan and breastfeeding?

A: Official documents address the use during lactation and typically state whether it is known if the active substance is excreted in human milk. Consultation with a healthcare professional is noted for specific guidance in this area.

Q: Can Risordan cause changes in mood?

A: While mood changes are not listed as common adverse reactions, the regulatory label includes other documented effects on the Nervous System.

Q: Is Risordan used outside of the United States?

A: Yes, official documents from European regulatory bodies, such as the EMA and MHRA, confirm that the active ingredient Isosorbide Dinitrate is approved and used across several international jurisdictions.

How should Risordan be stored and disposed of?

How to Store and Dispose of Risordan?

Risordan (Isosorbide Dinitrate) must be stored and disposed of according to specific conditions detailed in regulatory labeling to maintain product stability and ensure public safety.


Storage Conditions

Requirement Regulatory Statement
Temperature Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F).
Environment Must be kept away from excess heat and moisture and protected from light.
Prohibition The medicine must not be frozen.
Container Keep the container tightly closed and store in the original container.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

  • Do not keep outdated medicine or product that is no longer needed.
  • Consult a healthcare professional or pharmacist for official guidance on how to dispose of any unused medicine.
  • Disposal of unused product and container is typically managed through an approved waste disposal plant as per environmental protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Risordan found in:

A-Z Index: